AXIM Biotechnologies Engages Ocular Innovator Dr. Alan Touch as Regulatory Advisor

AXIM Biotechnologies, a diagnostic and biotechnology company specializing in ocular and inflammatory diseases, has strategically engaged 624 Advisors, owned and managed by Dr. Alan J. Touch, as its Chief Medical & Regulatory Affairs Advisor. This move brings a preeminent expert with over three decades of global leadership in diagnostics, medical devices, pharmaceuticals, and digital health to the company's team. Dr. Touch is not only the original co-inventor of the first ocular diagnostic technologies acquired by AXIM but also the inventor of the world's first colored contact lens, having previously held senior roles at Bausch & Lomb and served as Principal Strategist at INC Research (Syneos Health). His extensive background includes leading the development of proprietary dry eye disease products and founding 624 Advisors as a consultancy focused on product development, regulatory, and quality compliance.

According to Catalina Valencia, President and CEO of AXIM Biotechnologies, this engagement strengthens the company's R&D and regulatory capabilities, providing inventor-level knowledge of their technology combined with deep experience in FDA regulation, ISO quality systems, clinical development, and manufacturing readiness. Dr. Touch's involvement is designed to enhance AXIM's regulatory strategy, quality foundation, and clinical execution, positioning the company for efficient global expansion and long-term operational scale as it advances toward key milestones like FDA 510(k) submissions and international regulatory expansion. His unique alignment with AXIM's goals includes expertise in lactoferrin and immunoassay diagnostics, global regulatory frameworks, and proven leadership in scaling up manufacturing, which reduces reliance on external consultants and accelerates commercialization readiness.

Dr. Touch expressed enthusiasm for working with AXIM, noting his role in advancing technology he originally helped develop and supporting the company's efforts to build a strong foundation for regulatory excellence and clinical credibility. AXIM Biotechnologies, known for its TearScan® platform that enables point-of-care diagnostic tests for ocular and systemic health, aims to leverage this advisory role to enhance its market position. For more information, visit www.aximbiotech.com, and view the original release on www.newmediawire.com to see the full details of this strategic partnership and its implications for the biotechnology sector.